Media Update, page-1066

A positive economic study that has been published on FebriDx benefits for USA market. This type of positive coverage is good, as it often influences/triggers medical bodies to conduct further reviews+analysis on new medical devices/test/diagnosis methods. Such bodies in turn usually advise gov leaders and help shape national policies on public health tests, medical insurance coverage, reimbursement policies etc.

Fingers crossed more info like this comes out in favour of US national FebriDx adoption...post FDA approval & cost coverage

30 Sept'21 - Economic Evaluation of FebriDx: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States
_{https://jheor.org/article/27753-economic-evaluation-of-febridx-a-novel-rapid-point-of-care-test-for-differentiation-of-viral-versus-bacterial-acute-respiratory-infection-in-the-u}

"Objectives: The primary aim of this study is to conduct a literature-based US economic evaluation of a novel rapid point-of-care test, FebriDx®...."

"Methods: A budget impact model was developed based on a review of published literature on antibiotic prescribing for ARIs in the United States. The model considers the cost of antibiotic treatment, antibiotic resistant infections, antibiotic-related adverse events, and point-of-care testing. These costs were extrapolated to estimate savings on a national level."

"Results: The expected national cost to treat ARIs under standard of care was US $8.25 billion, whereas the expected national cost of FebriDx point-of-care-guided ARI treatment was US $5.74 billion. Therefore, the expected national savings associated with FebriDx® rapid point-of-care testing was US $2.51 billion annually.

Conclusions: FebriDx, a point of care test that can reliably aid in the differentiation of viral and bacterial infections, can reduce antibiotic misuse and, therefore, antibiotic resistant infections. This results in significant cost savings, driven primarily by the reduction in antibiotic resistant infections."